1-[2,8-bis(trifluoromethyl)-4-quinolinyl]-2-(methylamino)ethanol | 261000-66-2

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 喹啉及其衍生物
• 英文名称: 1-[2,8-bis(trifluoromethyl)-4-quinolinyl]-2-(methylamino)ethanol
• 英文别名: 1-(2,8-bis(trifluoromethyl)quinolin-4-yl)-2-(methylamino)ethanol；WR308245；α-Methylaminomethyl-2,8-bis(trifluoromethyl)-4-quinolinemethanol；1-[2,8-Bis(trifluoromethyl)quinolin-4-yl]-2-(methylamino)ethanol
• CAS: 261000-66-2
• 化学式: C₁₄H₁₂F₆N₂O
• 分子量: 338.252
• InChiKey: SXHYASJCSPRVCT-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.7
• 重原子数：
  23
• 可旋转键数：
  3
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.36
• 拓扑面积：
  45.2
• 氢给体数：
  2
• 氢受体数：
  9

反应信息

• 作为产物：
  描述：

  2-[2,8-二(三氟甲基)-4-喹啉基]环氧乙烷 在 甲胺 作用下， 以 水 为溶剂， 以72%的产率得到1-[2,8-bis(trifluoromethyl)-4-quinolinyl]-2-(methylamino)ethanol
  参考文献：
  名称：

  4-quinolinemethanol derivatives as purine receptor antagonists (II)

  摘要：

  使用以下公式（I）定义的化合物，或其药学上可接受的盐或前药，在制造用于治疗或预防阻断嘌呤受体尤其是腺苷受体，更具体地是A2a受体可能有益的疾病的药物中使用。这些疾病包括运动障碍，例如帕金森病或进行性核上性麻痹，亨廷顿病，多系统萎缩，皮质基底节变性，威尔逊病，霍勒德-斯巴茨病，进行性苍白球萎缩，多巴响应性肌张力障碍-帕金森综合征，痉挛性瘫痪，阿尔茨海默病或其他导致运动失调的基底节疾病。

  公开号：

  US06608085B1

文献信息

• Structure–activity relationships amongst 4-position quinoline methanol antimalarials that inhibit the growth of drug sensitive and resistant strains of Plasmodium falciparum
  作者：Erin Milner、William McCalmont、Jayendra Bhonsle、Diana Caridha、Dustin Carroll、Sean Gardner、Lucia Gerena、Montip Gettayacamin、Charlotte Lanteri、ThuLan Luong、Victor Melendez、Jay Moon、Norma Roncal、Jason Sousa、Anchalee Tungtaeng、Peter Wipf、Geoffrey Dow

  DOI：10.1016/j.bmcl.2010.01.001

  日期：2010.2

  Utilizing mefloquine as a scaffold, a next generation quinoline methanol (NGQM) library was constructed to identify early lead compounds that possess biological properties consistent with the target product pro. le for malaria chemoprophylaxis while reducing permeability across the blood-brain barrier. The library of 200 analogs resulted in compounds that inhibit the growth of drug sensitive and resistant strains of Plasmodium falciparum. Herein we report selected chemotypes and the emerging structure activity relationship for this library of quinoline methanols. Published by Elsevier Ltd.
• 4-QUINOLINEMETHANOL DERIVATIVES AS PURINE RECEPTOR ANTAGONISTS (II)
  申请人：VERNALIS RESEARCH LIMITED

  公开号：EP1107761A2

  公开（公告）日：2001-06-20
• US6608085B1
  申请人：——

  公开号：US6608085B1

  公开（公告）日：2003-08-19
• [EN] 4-QUINOLINEMETHANOL DERIVATIVES AS PURINE RECEPTOR ANTAGONISTS.(II)<br/>[FR] DERIVES DE 4-QUINOLINEMETHANOL UTILISES COMME ANTAGONISTES (II) DU RECEPTEUR DE PURINE
  申请人：CEREBRUS PHARM LTD

  公开号：WO2000013682A2

  公开（公告）日：2000-03-16

  Wherein: R1 is hydrogen or alkyl; R2 is selected from hydrogen, alkyl, aryl and 4,5,6,7 or 8 membered satured and partially unsaturated heterocyclic rings containing one or more heteroatoms selected from O, S and N; R3 and R4 are independently selected from hydrogen, alkyl, aryl, COR13, CO2R13, CONR13R14, CONR13NR14R15, SO2R13, SO2NR13R14, SO2NR13NR14R15 or may form a ring. Or R1 and R4 together may form a heterocyclic ring or R2 and R3 together may form a heterocyclic ring. R5 and R6 are independently selected from hydrogen, alkyl, aryl and heterocyclic with the proviso that where R3 and R5 together form a ring, then R3, and R4 do not also form a ring; or a pharmaceutically acceptable salt or prodrug thereof, in the manufacture of a medicament for the treatment or prevention of a disorder in which the blocking of purine receptors, particularly adenosine receptors and more particularly A2A receptors, may be beneficial, such as a movement disorder, for example, Parkinson's Disease or progressive supernuclear palsy, Huntingtons disease, multiple system atrophy, corticobasal degeneration, Wilsons disease, Hallerrorder-Spatz disease, progressive pallidal atrophy, Dopa-responsive dystonia-Parkinsonism, spasticity, Alzheimer's disease or other disorders of the basal ganglia which result in dyskinesias.
• [EN] COMPOSITIONS FOR THE TREATMENT OF CANCER AND USES THEREOF<br/>[FR] COMPOSITIONS DESTINÉES AU TRAITEMENT DU CANCER, ET LEURS UTILISATIONS
  申请人：UNIV FLORIDA

  公开号：WO2016209688A1

  公开（公告）日：2016-12-29

  The invention pertains to compositions comprising inhibitors of PI3K, AKT and/or mTOR, one or more 4-quinolinemethanols and a pharmaceutically acceptable excipient. These compositions can contain subtherapeutic amounts of each active ingredient (PI3K, AKT, mTOR, one or more 4-quinolinemethanols and various combinations thereof). The invention also provides a method of treating various forms of cancer, such as breast cancer, prostate cancer, multiple myeloma, hepatocyte carcinoma, brain cancer, lung cancer, non- small cell lung carcinoma, colorectal cancer, melanoma and/or pancreatic cancer.